JP2023515620A5 - - Google Patents

Info

Publication number
JP2023515620A5
JP2023515620A5 JP2022552208A JP2022552208A JP2023515620A5 JP 2023515620 A5 JP2023515620 A5 JP 2023515620A5 JP 2022552208 A JP2022552208 A JP 2022552208A JP 2022552208 A JP2022552208 A JP 2022552208A JP 2023515620 A5 JP2023515620 A5 JP 2023515620A5
Authority
JP
Japan
Prior art keywords
compound
formula
pharmaceutical composition
nucleic acid
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022552208A
Other languages
English (en)
Japanese (ja)
Other versions
JP7847852B2 (ja
JP2023515620A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/020153 external-priority patent/WO2021174164A1/en
Publication of JP2023515620A publication Critical patent/JP2023515620A/ja
Publication of JP2023515620A5 publication Critical patent/JP2023515620A5/ja
Priority to JP2026060544A priority Critical patent/JP2026108831A/ja
Application granted granted Critical
Publication of JP7847852B2 publication Critical patent/JP7847852B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022552208A 2020-02-28 2021-02-28 スプライシングを調節するための化合物及び方法 Active JP7847852B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026060544A JP2026108831A (ja) 2020-02-28 2026-04-01 スプライシングを調節するための化合物及び方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202062983541P 2020-02-28 2020-02-28
US62/983,541 2020-02-28
US202063007333P 2020-04-08 2020-04-08
US63/007,333 2020-04-08
US202063040484P 2020-06-17 2020-06-17
US63/040,484 2020-06-17
US202063072790P 2020-08-31 2020-08-31
US63/072,790 2020-08-31
US202063126492P 2020-12-16 2020-12-16
US63/126,492 2020-12-16
PCT/US2021/020153 WO2021174164A1 (en) 2020-02-28 2021-02-28 Compounds and methods for modulating splicing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026060544A Division JP2026108831A (ja) 2020-02-28 2026-04-01 スプライシングを調節するための化合物及び方法

Publications (3)

Publication Number Publication Date
JP2023515620A JP2023515620A (ja) 2023-04-13
JP2023515620A5 true JP2023515620A5 (cg-RX-API-DMAC7.html) 2025-08-22
JP7847852B2 JP7847852B2 (ja) 2026-04-20

Family

ID=75143749

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022552208A Active JP7847852B2 (ja) 2020-02-28 2021-02-28 スプライシングを調節するための化合物及び方法
JP2022552209A Active JP7736700B2 (ja) 2020-02-28 2021-02-28 複素環アミド及びスプライシングを調節するためのその使用
JP2025142246A Pending JP2025172876A (ja) 2020-02-28 2025-08-28 複素環アミド及びスプライシングを調節するためのその使用
JP2026060544A Pending JP2026108831A (ja) 2020-02-28 2026-04-01 スプライシングを調節するための化合物及び方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022552209A Active JP7736700B2 (ja) 2020-02-28 2021-02-28 複素環アミド及びスプライシングを調節するためのその使用
JP2025142246A Pending JP2025172876A (ja) 2020-02-28 2025-08-28 複素環アミド及びスプライシングを調節するためのその使用
JP2026060544A Pending JP2026108831A (ja) 2020-02-28 2026-04-01 スプライシングを調節するための化合物及び方法

Country Status (15)

Country Link
US (3) US20240190879A1 (cg-RX-API-DMAC7.html)
EP (3) EP4110464A1 (cg-RX-API-DMAC7.html)
JP (4) JP7847852B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220159386A (cg-RX-API-DMAC7.html)
CN (2) CN115485025A (cg-RX-API-DMAC7.html)
AU (2) AU2021228284A1 (cg-RX-API-DMAC7.html)
BR (2) BR112022017210A2 (cg-RX-API-DMAC7.html)
CA (2) CA3169691A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022002342A1 (cg-RX-API-DMAC7.html)
CO (2) CO2022013832A2 (cg-RX-API-DMAC7.html)
CR (2) CR20210483A (cg-RX-API-DMAC7.html)
IL (2) IL295956A (cg-RX-API-DMAC7.html)
MX (2) MX2022010684A (cg-RX-API-DMAC7.html)
SA (1) SA522440338B1 (cg-RX-API-DMAC7.html)
WO (3) WO2021174164A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
MX2020001425A (es) 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Metodos y composiciones para modular el empalme.
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163541A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
JP7603594B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
CA3139821A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
IL297963A (en) 2020-05-07 2023-01-01 Adorx Therapeutics Ltd Antagonists of the adenosine a2a receptor
WO2021231571A1 (en) 2020-05-13 2021-11-18 Chdi Foundation, Inc. Htt modulators for treating huntington's disease
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
IL311135A (en) 2021-08-30 2024-04-01 Remix Therapeutics Inc Compounds and methods for modulating splicing
MX2024002554A (es) 2021-08-30 2024-07-02 Remix Therapeutics Inc Compuestos y metodos para modular el empalme.
AU2022394333A1 (en) * 2021-11-17 2024-06-27 Chdi Foundation, Inc. HTT modulators for treating Huntington’s disease
CA3249778A1 (en) * 2022-06-15 2023-12-21 Ptc Therapeutics, Inc. HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF HUNTINGTON'S DISEASE
WO2024086569A1 (en) 2022-10-17 2024-04-25 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
WO2024086570A1 (en) 2022-10-17 2024-04-25 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
TW202440080A (zh) * 2023-03-01 2024-10-16 美商雷密克斯醫療公司 用於調節剪接之化合物及方法
WO2024182788A1 (en) * 2023-03-01 2024-09-06 Remix Therapeutics Inc. Compounds and methods for modulating splicing
TW202535379A (zh) * 2024-01-26 2025-09-16 大陸商成都微芯藥業有限公司 Usp1抑制劑及其製備方法和用途
CN118166099B (zh) * 2024-02-05 2024-10-22 北京大学深圳医院 检测hsa_circ_0014088的试剂在制备诊断口腔鳞状细胞癌的试剂盒中的应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4809656B2 (ja) * 2005-09-29 2011-11-09 富士フイルム株式会社 ナフタロシアニン色素およびその製造方法
US20070254894A1 (en) * 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
ME02789B (me) * 2006-08-08 2011-06-30 Millennium Pharm Inc Jedinjenja heteroarila korisna kao inhibitori e1 aktivirajućih enzima
WO2008040951A1 (en) 2006-10-03 2008-04-10 Astrazeneca Ab Compounds
US20100029657A1 (en) 2008-02-29 2010-02-04 Wyeth Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
GB0807910D0 (en) * 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
AU2009248774B2 (en) * 2008-05-23 2012-05-31 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
US20110288089A1 (en) 2009-01-22 2011-11-24 Syngenta Crop Protection Llc Insecticidal compounds
EP2435421A1 (en) 2009-05-29 2012-04-04 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
CN102020643A (zh) 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
TW201202230A (en) * 2010-05-24 2012-01-16 Mitsubishi Tanabe Pharma Corp Novel quinazoline compound
JP5826261B2 (ja) * 2010-06-28 2015-12-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 癌に対する使用のためのキナーゼ阻害剤としての2,4−ジアリール置換[1,8]ナフチリジン
JP2012028440A (ja) 2010-07-21 2012-02-09 Hitachi Kokusai Electric Inc 基板処理装置及び半導体装置の製造方法
EP3406252B1 (en) 2012-02-10 2020-05-13 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
CN104271568B (zh) 2012-05-09 2016-05-04 硕腾服务有限责任公司 作为抗寄生虫剂的氮杂环丁烷衍生物
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
EP2970312B1 (en) * 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
KR20140125061A (ko) * 2013-04-18 2014-10-28 (주)경인양행 유기발광 화합물 및 이를 포함하는 유기전계발광소자
CA2913785C (en) 2013-06-25 2021-08-31 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
MX375925B (es) 2014-06-25 2025-03-07 Hoffmann La Roche Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
WO2016004254A1 (en) * 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
US9862701B2 (en) 2014-09-25 2018-01-09 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
CN104341403B (zh) * 2014-10-10 2016-06-22 山东盛华电子新材料有限公司 一种2,5-二杂环取代萘基噁烷衍生物及其制备方法
NL2013636B1 (en) 2014-10-15 2016-10-04 Kraton Polymers Us Llc An accelerator system, a composition comprisng a synthetic isoprene polymer and the accelerator system, and dipped goods made from the composition.
EP3256126B1 (en) 2015-02-09 2024-03-27 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
CN106220644B (zh) * 2015-04-24 2020-07-31 广州再极医药科技有限公司 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
WO2017147328A1 (en) * 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
JP2019535789A (ja) 2016-11-28 2019-12-12 ピーティーシー セラピューティクス,インコーポレーテッド Rnaスプライシングを調節する方法
EP3573954A1 (en) * 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
EP4151627A1 (en) * 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
CN111372611A (zh) 2017-06-14 2020-07-03 Ptc医疗公司 修饰rna剪接的方法
MX2020001425A (es) 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Metodos y composiciones para modular el empalme.
US20230152257A1 (en) 2017-09-25 2023-05-18 Skyhawk Therapeutics, Inc. Methods and compositions for screening and identification of splicing
EP3697786B1 (en) * 2017-10-18 2022-08-31 Blueprint Medicines Corporation Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
TW201942115A (zh) * 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
JP2021521200A (ja) 2018-04-10 2021-08-26 スカイホーク・セラピューティクス・インコーポレーテッド 癌の処置のための化合物
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020004594A1 (ja) * 2018-06-27 2020-01-02 株式会社リボルナバイオサイエンス 脊髄性筋萎縮症の予防または治療剤
TWI834690B (zh) * 2018-07-18 2024-03-11 美商富曼西公司 用於防治無脊椎動物害蟲之異噁唑啉化合物
CN109180690A (zh) * 2018-10-15 2019-01-11 烟台显华化工科技有限公司 一类用作蓝色荧光材料的氮杂芳香化合物及其应用
US12503467B2 (en) * 2018-12-10 2025-12-23 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
US20220081412A1 (en) * 2018-12-20 2022-03-17 The Regents Of The University Of Michigan Quinolinyl-pyrazine-carboxamide compounds and uses thereof
KR20220012248A (ko) * 2019-04-22 2022-02-03 베타 파머수티컬 컴퍼니 리미티드 퀴나졸린 화합물 및 이의 의약품에서의 응용
WO2021007378A1 (en) * 2019-07-11 2021-01-14 Ptc Therapeutics, Inc. Compounds for use in treating huntington's disease

Similar Documents

Publication Publication Date Title
JP2023515621A5 (cg-RX-API-DMAC7.html)
JP2023515617A5 (cg-RX-API-DMAC7.html)
JP2023515618A5 (cg-RX-API-DMAC7.html)
JP2023520924A5 (cg-RX-API-DMAC7.html)
JP2023520916A5 (cg-RX-API-DMAC7.html)
JP2023520925A5 (cg-RX-API-DMAC7.html)
RU2020123151A (ru) Антагонисты tlr7/8 и их применение
JP2020521740A5 (cg-RX-API-DMAC7.html)
JP2022505835A5 (cg-RX-API-DMAC7.html)
IL295957A (en) Compounds and methods for modulating splicing
JP2024520481A5 (cg-RX-API-DMAC7.html)
JP2020521741A5 (cg-RX-API-DMAC7.html)
JP2016515096A (ja) スルファモイル−アリールアミドおよびb型肝炎を処置するための医薬品としてのその使用
JP2006525359A5 (cg-RX-API-DMAC7.html)
JP2019529490A5 (cg-RX-API-DMAC7.html)
JP2017533968A5 (cg-RX-API-DMAC7.html)
IL295955A (en) Compounds and methods for modulating splicing
RU2004126671A (ru) Гетероарилсоединения, полезные в качестве ингибиторов gsk-3
HRP20100670T1 (hr) Aril-supstituirani pirazol-amid spojevi korisni kao inhibitori kinaze
JP2014510774A5 (cg-RX-API-DMAC7.html)
JP2011037841A5 (cg-RX-API-DMAC7.html)
JP2013504593A5 (cg-RX-API-DMAC7.html)
RU2015107803A (ru) Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания
JP2013532652A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)